Skip to content

PACS Group

US · PACS #1809 by market cap Listed 2024
43.19 +0.38 +0.89%
Live - 5344 symbols - heartbeat 353s ago · 2026-10-08 05:18
Pre-market 43.00 -0.44%
After-hours 42.42 -1.79%
Market cap
6.84B
P/B
6.16
EPS
1.22
Reader sentiment Are you bullish or bearish on PACS?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Near fair value
19.37 fair value ≈ 36.05 52.74
  • Implied fair-value range of 19.37-52.74, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +19.8% above the average-multiple fair value of 36.05.

Valuation each multiple against its own 5-year range

P/B ratio 6.22 In line with history 62nd percentile
5-year average 9.53 · #32 of 40 in Medical Care Facilities
P/E ratio 25.51 In line with history 48th percentile
5-year average 29.55 · forward 18.06 · #20 of 30 in Medical Care Facilities
P/S ratio 1.24 Expensive vs history 73rd percentile
5-year average 0.96 · forward 1.12 · #33 of 50 in Medical Care Facilities

Vs. peers Medical Care Facilities

Company Market cap P/E (TTM) P/B Div yield
PACS Group (PACS) 6.84B 25.26 6.16 0.00%
HCA Healthcare (HCA) 95.08B 14.73 -14.32 0.68%
Tenet Healthcare (THC) 20.92B 10.04 4.49 0.00%
Encompass Health (EHC) 12.08B 19.95 4.65 0.62%
DaVita (DVA) 11.28B 14.57 -14.74 0.00%
Fresenius Medical Care (FMS) 11.01B 11.14 0.78 4.13%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value38.72 Economic moatNarrow UncertaintyHigh

Trading 10.4% above Morningstar's fair value estimate.

Fair value

PACS Group Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 10% premium over our quantitative fair value estimate of $38.72 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 16.4%, which lies in the bottom 20% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The company's unfavorable dividend structure is an additional cause for concern. Dividends represent a stable form of future cash flows returned to shareholders, and low dividend payments can increase the perceived risk of a business. The firm's forward dividend yield of 0%, for example, sits in the bottom 30% globally. This could imply a planned dividend cut or relatively high share price, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 05:18:54 · For reference only, not investment advice and not tailored to your situation.